Phase 1b Escalating Study to Evaluate the Safety and Immunogenicity of Recombinant Ricin Toxin A-Chain 1-33/44-198 (rRTA 1-33/44-198) Vaccine (RVEc) Administered Intramuscularly to Healthy Adults as a 3-Dose Primary Series and Booster
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 04 Mar 2017
At a glance
- Drugs Ricin vaccine (Primary)
- Indications Ricin poisoning
- Focus Adverse reactions
- 28 Feb 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 24 Nov 2015 Planned initiation date changed from 1 Oct 2015 to 1 Apr 2016 as reported by ClinicalTrials.gov record.
- 03 May 2015 Planned initiation date changed from 1 May 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov record.